Novo CEO calls Wegovy problems "a perfect storm," will not move production in-house
A productions halt at a US-based subcontractor has been a fly in the ointment for the launch of Novo’s obesity drug Wegovy. However, CEO Lars Fruergaard Jørgensen isn’t considering bringing more of the production chain in-house in the future.
by ANDREAS LØNSTRUP, translated by daniel pedersen
Serious production problems at one of Novo Nordisk’s subcontractors have meant that the Danish pharmaceutical company won’t be able to meet the full demand of its newly launched obesity treatment, Wegovy.